# Igor Bondarenko

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/igor-bondarenko/

## Facts

| Field | Value |
| --- | --- |
| Citations | 55,440 |
| Field | Lung Cancer Research Studies |
| h-index | 83 |
| i10-index | 213 |
| Last Known Institution | Dnipro State Medical University |
| OpenAlex ID | https://openalex.org/A5019547742 |
| ORCID iD | https://orcid.org/0000-0002-7071-2471 |
| Works | 630 |

## Researcher papers

- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer](https://scholariq.org/papers/ribbon-1-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial](https://scholariq.org/papers/docetaxel-plus-nintedanib-versus-docetaxel-plus-placebo-in-patients-with/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-first-line-serplulimab-vs-placebo-added-to-chemotherapy-on-survival-in/)
- [Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer](https://scholariq.org/papers/trifluridine-tipiracil-and-bevacizumab-in-refractory-metastatic-colorectal/)
- [Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-in-resected-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer](https://scholariq.org/papers/randomized-phase-iii-placebo-controlled-trial-of-letrozole-plus-oral/)
- [A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy](https://scholariq.org/papers/a-randomized-phase-iii-study-evaluating-the-efficacy-and-safety-of-nepa-a-fixed/)
- [Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study](https://scholariq.org/papers/efficacy-and-safety-of-nepa-an-oral-combination-of-netupitant-and-palonosetron/)

## Researcher topics

- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Researcher university

- [Dnipro State Medical University](https://scholariq.org/institutions/dnipro-state-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.